Due to early symptoms of thoracic cancer being hidden, the majority of cases are diagnosed with intermediate to the advanced stage, which has a substantial unfavorable influence on the patient’s therapeutic effect and survival. The patients are now difficult to benefit from the therapy of solo surgery on survival.
Neoadjuvant treatment has been shown in several studies to increase postoperative survival and decrease recurrence and metastasis of esophageal cancer. Choose an operational adjuvant therapy that might prolong patient survival based on the findings of the postoperative pathology. However, there is still debate over which regimen is superior or inferior. Even yet, concerns such as medication resistance, tumor cell immune evasion, therapeutic adverse events, and others are still regarded as crucial focal points in the treatment of esophageal cancer. The largest problem for researchers is how to balance and match the ideal therapy regimen for thoracic cancer from a range of perioperative therapy, including radiation, chemotherapy, and immunotherapy, which is the biggest challenge for researchers. Therefore, all neoadjuvant and adjuvant therapy approaches should be included in a thorough knowledge of the interactions between perioperative therapy and efficacy in thoracic cancer.
This special issue is to collect novel contributions in Original Research, Clinical Trials, and Review articles to the topic focusing on neoadjuvant or adjuvant therapy of thoracic cancer. We aim to generate opportunities for future research where advanced knowledge can be translated into potential therapeutic strategies in cancers.
In this special issue, we welcome articles highlighting the current points of thoracic cancer, neoadjuvant therapy, adjuvant therapy, and biomarkers associated with therapy response. In detail, the bullet points of this field are included below:
1) Therapeutic effect and mechanism of perioperative therapy (radiotherapy, chemotherapy, immunotherapy, and others) or combination multiple combination regimens in thoracic cancer;
2) Potential mechanisms underlying how cancers evade the immune surveillance or drug resistance;
3) Identification of underlying biomarkers for esophageal cancer immunogenicity, immune infiltrates, and prognosis;
4) Molecular mechanism of biocompatibility and responsiveness toward tumor microenvironment;
5) Other potential combination therapeutic strategies.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Due to early symptoms of thoracic cancer being hidden, the majority of cases are diagnosed with intermediate to the advanced stage, which has a substantial unfavorable influence on the patient’s therapeutic effect and survival. The patients are now difficult to benefit from the therapy of solo surgery on survival.
Neoadjuvant treatment has been shown in several studies to increase postoperative survival and decrease recurrence and metastasis of esophageal cancer. Choose an operational adjuvant therapy that might prolong patient survival based on the findings of the postoperative pathology. However, there is still debate over which regimen is superior or inferior. Even yet, concerns such as medication resistance, tumor cell immune evasion, therapeutic adverse events, and others are still regarded as crucial focal points in the treatment of esophageal cancer. The largest problem for researchers is how to balance and match the ideal therapy regimen for thoracic cancer from a range of perioperative therapy, including radiation, chemotherapy, and immunotherapy, which is the biggest challenge for researchers. Therefore, all neoadjuvant and adjuvant therapy approaches should be included in a thorough knowledge of the interactions between perioperative therapy and efficacy in thoracic cancer.
This special issue is to collect novel contributions in Original Research, Clinical Trials, and Review articles to the topic focusing on neoadjuvant or adjuvant therapy of thoracic cancer. We aim to generate opportunities for future research where advanced knowledge can be translated into potential therapeutic strategies in cancers.
In this special issue, we welcome articles highlighting the current points of thoracic cancer, neoadjuvant therapy, adjuvant therapy, and biomarkers associated with therapy response. In detail, the bullet points of this field are included below:
1) Therapeutic effect and mechanism of perioperative therapy (radiotherapy, chemotherapy, immunotherapy, and others) or combination multiple combination regimens in thoracic cancer;
2) Potential mechanisms underlying how cancers evade the immune surveillance or drug resistance;
3) Identification of underlying biomarkers for esophageal cancer immunogenicity, immune infiltrates, and prognosis;
4) Molecular mechanism of biocompatibility and responsiveness toward tumor microenvironment;
5) Other potential combination therapeutic strategies.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
